Gerster John F, Lindstrom Kyle J, Miller Richard L, Tomai Mark A, Birmachu Woubalem, Bomersine Shannon N, Gibson Shiela J, Imbertson Linda M, Jacobson Joel R, Knafla Roy T, Maye Peter V, Nikolaides Nickolas, Oneyemi Folakemi Y, Parkhurst Gwen J, Pecore Sharon E, Reiter Michael J, Scribner Lisa S, Testerman Tracy L, Thompson Natalie J, Wagner Tammy L, Weeks Charles E, Andre Jean-Denis, Lagain Daniel, Bastard Yvon, Lupu Michel
3M Pharmaceuticals, 3M Center, Building 270-4S-02, St. Paul, Minnesota 55144-1000, USA.
J Med Chem. 2005 May 19;48(10):3481-91. doi: 10.1021/jm049211v.
1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogues as potential antiviral agents. While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. We have determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, we found that the compounds also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.
在研究新型核苷类似物作为潜在抗病毒药物的过程中,制备了1H-咪唑并-[4,5-c]喹啉。虽然这些化合物在多个细胞培养系统中测试时未显示出直接的抗病毒活性,但在阴道内豚鼠单纯疱疹病毒-2试验中,一些化合物表现出对病毒损伤发展的强效抑制作用。我们已经确定,在该模型中,体内抗病毒活性可归因于这些分子诱导细胞因子产生的能力,尤其是干扰素(IFN)。随后,我们发现这些化合物还能在人外周血单核细胞(hPBMCs)中诱导体外IFN的产生。本文报道的体外结果和先前报道的体内结果导致了咪喹莫特(26)的发现,咪喹莫特已被开发为一种局部用药,并已被批准用于治疗尖锐湿疣、光化性角化病和浅表基底细胞癌。